$AMPE Recent Headlines
Friday’s biggest gaining and declining stocks 3:26 p.m. July 13, 2012 - MarketWatch
Stocks to watch Friday: Lexmark, New York & Co. 5:47 a.m. July 13, 2012 - MarketWatch
Monday’s biggest gaining and declining stocks 3:50 p.m. June 11, 2012 - MarketWatch
Ampio: Optina has potential for diabetic treatment 11:46 a.m. June 11, 2012 - MarketWatch.com
Ampio shares add 27% after positive trial results 6:26 a.m. June 11, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 12:50 p.m. March 20, 2012 - Kate Gibson
Ampio rallies on eye-drug study 11:52 a.m. March 19, 2012 - Val Brickates Kennedy
Ampio tumbles on stock placement 2:50 p.m. Dec. 21, 2011 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 4:38 p.m. Dec. 19, 2011 - Greg Morcroft
Ampio Pharmaceuticals tumbles on drug concerns 2:57 p.m. Dec. 15, 2011 - Val Brickates Kennedy
Cramer's Lightning Round - The Andersons Must Be Doing Something Right (11/13/13) 6:18 a.m. Nov. 14, 2013 - Seeking Alpha
'Mad Money' Lightning Round: Tired of Union Pacific 6:00 a.m. Nov. 14, 2013 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Bears Overwhelmed 8:17 p.m. Nov. 13, 2013 - TheStreet.com
Ampio AWOL With Knee-Pain Drug Data Disclosures 7:00 a.m. Nov. 12, 2013 - TheStreet.com
Ampio Pharma Announces Results from Panel Review of the Interim Analysis of the Optina(TM) Trial, FDA Agrees to 505(B) 2 Pathway 6:07 a.m. Oct. 7, 2013 - benzinga.com
Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial 6:09 a.m. Sept. 30, 2013 - benzinga.com
Ampio Momentum Continues After Positive Initial Phase III Data 2:57 p.m. Aug. 26, 2013 - Seeking Alpha
Strong Phase III Ampion Data Released Wednesday: Setting The Stage For Ampio 7:12 a.m. Aug. 15, 2013 - Seeking Alpha
10-Q: AMPIO PHARMACEUTICALS, INC. 4:06 p.m. Aug. 9, 2013 - Edgar Online - (EDG = 10Q, 10K)
Raghuram 'Ram' Selvaraju On The Best Biotech Ideas Of 2013 7:20 a.m. July 22, 2013 - Seeking Alpha
What The Snubbing Of Hyaluronic Acid By The AAOS Means For Investors 8:41 a.m. June 25, 2013 - Seeking Alpha
Ampio Pharma's Luoxis Diagnostics Reports Positive Results from First Study of Proprietary Diagnostic Platform 6:06 a.m. June 20, 2013 - benzinga.com
Ampio Pharmaceuticals: 50 Shades Of Grey - Secondary On The Way 3:53 p.m. June 6, 2013 - Seeking Alpha
2 Potentially Explosive Small Cap Stocks For 2013 3:53 a.m. May 30, 2013 - Seeking Alpha
Regeneron Shareholders Watching Optina Trial Closely 2:56 p.m. May 22, 2013 - Seeking Alpha
10-Q: AMPIO PHARMACEUTICALS, INC. 4:04 p.m. May 3, 2013 - Edgar Online - (EDG = 10Q, 10K)
Ampio Pharma Initiates Phase III, Investors Extend Momentum 8:39 a.m. May 3, 2013 - Seeking Alpha
Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee 6:03 a.m. April 25, 2013 - benzinga.com
Lucrative AMD And DME Markets Attract Wall Street To Regeneron And Other Players 12:43 p.m. April 3, 2013 - Seeking Alpha
Ampio Receives FDA Acceptance for Clinical Trial of Ampion for Treatment of Osteoarthritis of the Knee 4:05 a.m. April 2, 2013 - benzinga.com
AMPIO PHARMACEUTICALS, INC. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Ampio Pharmaceuticals, Inc. 5:54 p.m. Today - PR Newswire
Ampio Pharmaceuticals to Present at Upcoming Investor Conference 8:00 a.m. Nov. 15, 2013 - PR Newswire
Ampio Pharmaceuticals Reports Positive Results in the Extended Spring study of Osteoarthritis of the Knee Following a Single Intra-articular Injection of Ampion(TM) 8:00 a.m. Nov. 4, 2013 - PR Newswire
Ampio Pharmaceuticals, Inc. States that its Policy is Not to Comment on Unusual Market Activity 7:00 a.m. Oct. 25, 2013 - PR Newswire
Emerging Growth Equities, Ltd. Initiates Coverage Of Ampio Pharmaceuticals, Inc. (AMPE) With A BUY Rating And $14.00 Price Target 9:21 a.m. Oct. 11, 2013 - PR Newswire
Ampio Pharmaceuticals, Inc. Announces Positive Results from Independent Panel Review of the Interim Analysis of the Optina(TM) Trial for Diabetic Macular Edema 7:00 a.m. Oct. 7, 2013 - PR Newswire
Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of company's third US patent for its oxidation-reduction potential diagnostic platform 7:00 a.m. Oct. 1, 2013 - PR Newswire
Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial 7:00 a.m. Sept. 30, 2013 - PR Newswire
Ampio Pharmaceuticals, Inc. Announces $25 Million Financing 5:00 a.m. Sept. 26, 2013 - PR Newswire
Five Star Equities Issues New Research Reports on AMPE, BIOS, MM and XONE 7:31 a.m. Aug. 15, 2013 - ACCESSWIRE
Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial 7:00 a.m. Aug. 14, 2013 - PR Newswire
Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog 7:00 a.m. June 7, 2013 - PR Newswire
Ampio Pharmaceuticals to List on the NYSE MKT 7:00 a.m. June 6, 2013 - PR Newswire
Ampio Pharmaceuticals Provides Clinical Updates 7:00 a.m. June 3, 2013 - PR Newswire
Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference 7:00 a.m. May 13, 2013 - PR Newswire
Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee 7:00 a.m. April 25, 2013 - PR Newswire
Ampio Receives FDA Clearance to Initiate Clinical Trial of Ampion(TM) for the Treatment of Osteoarthritis of the Knee: Patient Treatments have begun. 3:00 a.m. April 2, 2013 - PR Newswire
Ampio Receives FDA Acceptance of its Patient Outcome for Premature Ejaculation (POPE) Questionnaire, Paving the Way for its US Pivotal Trial on Zertane(TM) 3:00 a.m. March 11, 2013 - PR Newswire
LifeSci Advisors Initiates Coverage of Ampio Pharmaceuticals 8:02 a.m. March 7, 2013 - Marketwire
Ampio Pharmaceuticals Initiates Clinical Trial of Optina(TM) in Diabetic Macular Edema (DME): First Patient Dosed 4:00 a.m. Feb. 27, 2013 - PR Newswire
Friday’s biggest gaining and declining stocks 3:26 p.m. July 13, 2012 - MarketWatch
Stocks to watch Friday: Lexmark, New York & Co. 5:47 a.m. July 13, 2012 - MarketWatch
Monday’s biggest gaining and declining stocks 3:50 p.m. June 11, 2012 - MarketWatch
Ampio: Optina has potential for diabetic treatment 11:46 a.m. June 11, 2012 - MarketWatch.com
Ampio shares add 27% after positive trial results 6:26 a.m. June 11, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 12:50 p.m. March 20, 2012 - Kate Gibson
Ampio rallies on eye-drug study 11:52 a.m. March 19, 2012 - Val Brickates Kennedy
Ampio tumbles on stock placement 2:50 p.m. Dec. 21, 2011 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 4:38 p.m. Dec. 19, 2011 - Greg Morcroft
Ampio Pharmaceuticals tumbles on drug concerns 2:57 p.m. Dec. 15, 2011 - Val Brickates Kennedy
Cramer's Lightning Round - The Andersons Must Be Doing Something Right (11/13/13) 6:18 a.m. Nov. 14, 2013 - Seeking Alpha
'Mad Money' Lightning Round: Tired of Union Pacific 6:00 a.m. Nov. 14, 2013 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Bears Overwhelmed 8:17 p.m. Nov. 13, 2013 - TheStreet.com
Ampio AWOL With Knee-Pain Drug Data Disclosures 7:00 a.m. Nov. 12, 2013 - TheStreet.com
Ampio Pharma Announces Results from Panel Review of the Interim Analysis of the Optina(TM) Trial, FDA Agrees to 505(B) 2 Pathway 6:07 a.m. Oct. 7, 2013 - benzinga.com
Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial 6:09 a.m. Sept. 30, 2013 - benzinga.com
Ampio Momentum Continues After Positive Initial Phase III Data 2:57 p.m. Aug. 26, 2013 - Seeking Alpha
Strong Phase III Ampion Data Released Wednesday: Setting The Stage For Ampio 7:12 a.m. Aug. 15, 2013 - Seeking Alpha
10-Q: AMPIO PHARMACEUTICALS, INC. 4:06 p.m. Aug. 9, 2013 - Edgar Online - (EDG = 10Q, 10K)
Raghuram 'Ram' Selvaraju On The Best Biotech Ideas Of 2013 7:20 a.m. July 22, 2013 - Seeking Alpha
What The Snubbing Of Hyaluronic Acid By The AAOS Means For Investors 8:41 a.m. June 25, 2013 - Seeking Alpha
Ampio Pharma's Luoxis Diagnostics Reports Positive Results from First Study of Proprietary Diagnostic Platform 6:06 a.m. June 20, 2013 - benzinga.com
Ampio Pharmaceuticals: 50 Shades Of Grey - Secondary On The Way 3:53 p.m. June 6, 2013 - Seeking Alpha
2 Potentially Explosive Small Cap Stocks For 2013 3:53 a.m. May 30, 2013 - Seeking Alpha
Regeneron Shareholders Watching Optina Trial Closely 2:56 p.m. May 22, 2013 - Seeking Alpha
10-Q: AMPIO PHARMACEUTICALS, INC. 4:04 p.m. May 3, 2013 - Edgar Online - (EDG = 10Q, 10K)
Ampio Pharma Initiates Phase III, Investors Extend Momentum 8:39 a.m. May 3, 2013 - Seeking Alpha
Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee 6:03 a.m. April 25, 2013 - benzinga.com
Lucrative AMD And DME Markets Attract Wall Street To Regeneron And Other Players 12:43 p.m. April 3, 2013 - Seeking Alpha
Ampio Receives FDA Acceptance for Clinical Trial of Ampion for Treatment of Osteoarthritis of the Knee 4:05 a.m. April 2, 2013 - benzinga.com
AMPIO PHARMACEUTICALS, INC. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Ampio Pharmaceuticals, Inc. 5:54 p.m. Today - PR Newswire
Ampio Pharmaceuticals to Present at Upcoming Investor Conference 8:00 a.m. Nov. 15, 2013 - PR Newswire
Ampio Pharmaceuticals Reports Positive Results in the Extended Spring study of Osteoarthritis of the Knee Following a Single Intra-articular Injection of Ampion(TM) 8:00 a.m. Nov. 4, 2013 - PR Newswire
Ampio Pharmaceuticals, Inc. States that its Policy is Not to Comment on Unusual Market Activity 7:00 a.m. Oct. 25, 2013 - PR Newswire
Emerging Growth Equities, Ltd. Initiates Coverage Of Ampio Pharmaceuticals, Inc. (AMPE) With A BUY Rating And $14.00 Price Target 9:21 a.m. Oct. 11, 2013 - PR Newswire
Ampio Pharmaceuticals, Inc. Announces Positive Results from Independent Panel Review of the Interim Analysis of the Optina(TM) Trial for Diabetic Macular Edema 7:00 a.m. Oct. 7, 2013 - PR Newswire
Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of company's third US patent for its oxidation-reduction potential diagnostic platform 7:00 a.m. Oct. 1, 2013 - PR Newswire
Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial 7:00 a.m. Sept. 30, 2013 - PR Newswire
Ampio Pharmaceuticals, Inc. Announces $25 Million Financing 5:00 a.m. Sept. 26, 2013 - PR Newswire
Five Star Equities Issues New Research Reports on AMPE, BIOS, MM and XONE 7:31 a.m. Aug. 15, 2013 - ACCESSWIRE
Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial 7:00 a.m. Aug. 14, 2013 - PR Newswire
Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog 7:00 a.m. June 7, 2013 - PR Newswire
Ampio Pharmaceuticals to List on the NYSE MKT 7:00 a.m. June 6, 2013 - PR Newswire
Ampio Pharmaceuticals Provides Clinical Updates 7:00 a.m. June 3, 2013 - PR Newswire
Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference 7:00 a.m. May 13, 2013 - PR Newswire
Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee 7:00 a.m. April 25, 2013 - PR Newswire
Ampio Receives FDA Clearance to Initiate Clinical Trial of Ampion(TM) for the Treatment of Osteoarthritis of the Knee: Patient Treatments have begun. 3:00 a.m. April 2, 2013 - PR Newswire
Ampio Receives FDA Acceptance of its Patient Outcome for Premature Ejaculation (POPE) Questionnaire, Paving the Way for its US Pivotal Trial on Zertane(TM) 3:00 a.m. March 11, 2013 - PR Newswire
LifeSci Advisors Initiates Coverage of Ampio Pharmaceuticals 8:02 a.m. March 7, 2013 - Marketwire
Ampio Pharmaceuticals Initiates Clinical Trial of Optina(TM) in Diabetic Macular Edema (DME): First Patient Dosed 4:00 a.m. Feb. 27, 2013 - PR Newswire
